A record number of new biotech medicines are now under development, according to a report from the Pharmaceutical Research and Manufacturers of America (PhRMA) on the next generation of medicines in research pipelines. The report found that America’s pharmaceutical research and biotechnology companies are testing 633 new biotech medicines.
All of the experimental medicines in the report are being tested in human clinical trials or await approval by the US Food and Drug Administration.
The 633 biotechnology medicines being developed by companies nationwide include 254 medicines for cancer, 162 for infectious diseases, 59 for autoimmune diseases, 34 for HIV/AIDS and related conditions, 25 for cardiovascular disease, and 19 for diabetes and related conditions. The medicines include a number of innovative approaches, such as a laboratory-made version of a naturally-occurring protein that neutralizes foreign invaders.
Release date: September 24, 2008
Source: Pharmaceutical Research and Manufacturers of America (PhRMA)
Filed Under: Drug Discovery